JAZZPHARMA COTIZA EN LOS 129 DÓLARES Y MORGAN STANLEY Eleva el Precio Objetivo de JAZZ PHARMACEUTICALS a 167 DÓLARES DESDE 163 $ ... Mientras TRUIST SECURITIES Ha Elevado su Precio Objetivo Para JAZZ Pharma a 205 DÓLARES .

 

IMFORTE . LURBINECTEDIN ( BY PHARMAMAR / JAZZPHARMA ) / ATEZOLIZUMAB ( BY ROCHE / GENENTECH ) ... CITA TOPE CON LA US FDA EL PRÓXIMO 7 DE OCTUBRE 2025 .

Jazz Pharmaceuticals plc (JAZZ) .

Jazz Pharma's Zepzelca, in combination with Roche's Tecentriq as a first-line maintenance treatment for people with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with Tecentriq, carboplatin, and etoposide, is under Priority Review by the FDA, with a decision due on October 7, 2025.

In a phase III trial, Zepzelca plus Tecentriq demonstrated statistically significant and clinically meaningful improvements in both progression-free and overall survival in the extensive-stage small cell lung cancer first-line maintenance setting.

Zepzelca received the FDA's accelerated approval in June 2020 for the treatment of adult patients with metastatic small-cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

The drug generated annual net product sales of $320.3 million in 2024, up 11% over the prior year.